SecBot SecBot
8-K ·Filed Jul 29, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001193125-26-324202
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine severance amendment with no trading signal. Monitor the Q3 2026 10-Q for full agreement exhibits if detail on base salary and bonus targets is needed. No immediate catalyst for KURA shares.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.31
T+0 close · Jul 29, 2026 · via day close
Latest settled
+3.22%
T+60 · $9.61
Vs SPY
+0.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $9.31entry
  2. T+1 · 4mo ago −3.22%α −3.93% · $9.01
  3. T+5 · 3mo ago −0.32%α −3.94% · $9.28
  4. T+20 · 3mo ago +41.57%α +37.60% · $13.18
  5. T+60 · 25d ago +3.22%α +0.76% · $9.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology entered amended executive employment agreements with its CEO, CCO, and COO modifying severance provisions. The changes enhance change-of-control severance benefits (e.g., 24-month salary for CEO in change-of-control termination, full equity acceleration). No departures, appointments, or material financial figures were disclosed.

Key Facts

  • CEO Troy E. Wilson's new agreement provides 12 months base salary severance (non-change-of-control) or 24 months + 200% target bonus (change-of-control).
  • CCO Brian Powl and COO Kathleen Ford each receive 12 months base salary severance (non-change-of-control) or 18 months + 150% target bonus (change-of-control).
  • Change-of-control severance includes full equity acceleration (performance-based awards vest at target) for all three executives.
  • Full copies of the agreements will be filed with the Q3 2026 10-Q.

Financial Impact

No dollar amounts disclosed; impact is contingent on undefined severance scenarios (base salary and target bonus values not provided).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-324202
Document: 0001193125-26-324202-index-headers.html0001193125-26-324202
Document: 0001193125-26-324202-index.html0001193125-26-324202
Document: 0001193125-26-324202.txt0001193125-26-324202

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026